Status:
COMPLETED
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
3-18 years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 1 Diabetes
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT00097071
Start Date
October 1 2004
End Date
May 1 2006
Last Update
December 22 2016
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mobile, Alabama, United States, 36617
2
Novo Nordisk Investigational Site
Montgomery, Alabama, United States, 36106
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85016
4
Novo Nordisk Investigational Site
Little Rock, Arkansas, United States, 72202